-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
I believe that many people have suffered from dermatitis, especially atopic dermatitis (AD).
The pathophysiology of atopic dermatitis involves many factors, including host genetics, changes in skin barrier function, and immune abnormalities.
On February 22, 2021, the Richard L.
First, the research team conducted selection and preclinical testing of symbiotic bacteria that are beneficial to human skin.
Subsequently, the researchers evaluated the safety of ShA9 on the skin of participants with AD, and designed a randomized, double-blind phase 1 human clinical trial to better understand the mechanism of action and explore the effects of ShA9 on humans.
The included population was adults with moderate to severe AD on the ventral arm (n = 54), and patients with positive Staphylococcus aureus cultures.
The results of the trial showed that participants who received ShA9 had fewer adverse events related to AD.
In short, the researchers proposed that the best treatment for AD is to restore the epidermal barrier defect while suppressing the cause of inflammation.
Reference materials:
[1] https://
